linjc16/ctgov huggingface dataset:
In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

Study Overview
=================
Brief Summary
-----------------
This is a pilot study to evaluate the findings of the Reflectance Confocal Microscopy when performed in cutaneous pigmentary disorders, such as vitiligo, melasma, post-inflammatory hyper-pigmentation and hypo-pigmentation. Confocal Microscopy is a recent diagnostic technique that has been used for observation of skin conditions that affect the superficial layers of the skin.

Official Title
-----------------
In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

Conditions
-----------------
Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 20-70 years of age. Clinical diagnosis of vitiligo, melasma, post-inflammatory hypo or depigmentation or post-inflammatory hyperpigmentation. Willing and able to understand and sign informed consent. Able to complete study and comply with study procedures. Exclusion Criteria: Use of topical therapies such as corticosteroids, protopic, hydroquinone and azelaic acid within the past 2 months. Use of light therapy such as narrow-band-UVB, PUVA or laser within the past 2 months. Intake of medications that can cause pigmentary changes within the past year. Examples are: Antimalarials (chloroquine, hydroxychloroquine) Chemotherapeutics (bleomycin, busulfan, doxorubicin, daunorubicin, fluorouracil, cyclophosphamide, and carmustine) Heavy metals (gold, silver, bismuth, and mercury) Tetracyclines (including minocycline, doxycycline) Amiodarone Azidothymidine Clofazimine Clinically significant abnormal findings or conditions (other than the pigmentary disorder), which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study. Subjects who are known to be pregnant or planning a pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Subjects with vitiligo. | |
| 2<br>Subjects with melasma. | |
| 3<br>Subjects with post-inflammatory hyper-pigmentation. | |
| 4<br>Subjects with post-inflammatory hypo-pigmentation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe characteristic features seen by confocal microscopy of several pigmentary disorders. |  | study visit |
Epidemiological Study on Community Acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia.

Detailed Description
-----------------
Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia. The aim of the study CAPNETZ is to improve diagnosis, treatment and patient care.

Official Title
-----------------
Epidemiological Study on Community Acquired Pneumonia

Conditions
-----------------
Community Acquired Pneumonia

Intervention / Treatment
-----------------
* Other: Cohort Study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 infiltrate on chest X-ray further Inclusion criteria: cough or production of purulent sputum or pathologic lung auscultation (crackles) or fever Exclusion Criteria: hospital inpatient treatment within the last 28 days Immune suppressed patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with pneumonia<br> | Other: Cohort Study<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnosis | Assessment of diagnosis: Patients will be asked for example, about their diagnosis, comorbidities, specific risk factors and pneumonia symptoms. | 2 weeks | 
| therapy | Assessment of therapy: Patients will be asked about their therapy due to pneumonia symptoms, previous therapy, medication History etc. | 2 weeks | 
| hospitalization | Assessment of hospitalization: Patients will be asked about hospitalization, date, time and duration of hospitalization due to pneumonia symptoms. | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fever, Community acquired pneumonia, CAP, CAPNETZ, age ≥18, infiltrate on chest X-ray, cough or production of purulent sputum, pathologic lung auscultation
Joovvin' for Your Skin Health Study

Study Overview
=================
Brief Summary
-----------------
Sixty day single arm trial examining self-report and remote dermatology assessment of cosmetic skin health after daily 10-20 minute sessions with an infrared light therapy device (the Joovv Mini)

Official Title
-----------------
Examining the Impact of Infrared Light Therapy Device on Cosmetic Skin Health

Conditions
-----------------
Skin Inflammation, Acne, Skin Diseases, Dermatological Non-Disease, Skin Condition, Eczema

Intervention / Treatment
-----------------
* Device: Joovv Mini


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: willingness to use device for 60 days willingness to place security deposit on device of $149.99 US resident with an address than can accept UPS deliveries 18 years old no serious medical conditions no medically treatable skin diseases willingness to take a selfie with mobile phone Exclusion Criteria: Retinoid use prior use of light therapy within the past 6 months pregnant or nursing dietary supplements for skin, hair or nail health

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Arm<br>Participants will receive an infrared therapy device for use at home for 60 days. Participants will use the device every day for 10-20 minutes during the intervention period. | Device: Joovv Mini<br>* Infrared light therapy uses certain wavelengths of light that are delivered to the face. This study will use the Joovv Mini.<br>* Other names: Infrared light therapy device;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blinded Dermatology Assessment of Facial Skin Health | Comparison over timepoints of physician assessment of facial features at rest and smile to the Glogau & custom wrinkle selfie scale | 60 day | 
| Changes in Self-Report Skin, Hair & Nail Health and Satisfaction | A custom self report survey on cosmetic skin health satisfaction | 60 day |
Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19

Study Overview
=================
Brief Summary
-----------------
Determination of IgM and IgG antibodies against SARS-CoV-2 in dialysis patients by continous monitoring in the period from March 2020 to december 2020

Detailed Description
-----------------
Blood samples are collected every 14 days

Official Title
-----------------
Antistof Respons Mod SARS-CoV-2 Hos Dialysepatienter i Forbindelse Med COVID-19

Conditions
-----------------
COVID, Terminal Renal Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dialysis Exclusion Criteria: Not willing to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AAntibody response | IgM and IgG against SARS-CoV-2 | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, CKD 5
Use Of Virtual Reality For Pain Control in Dermatological Bedside Procedures

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to explore the impact of virtual reality (VR) on pain perception during out-patient procedures such as wart removal, wound debridement, and lidocaine injections.

Official Title
-----------------
Use Of Virtual Reality For Pain Control in Dermatological Bedside Procedures

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Other: Oculus Go Virtual Reality System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 13 years and older. Patient (or health care proxy when applicable) must sign an ICF. Patient requiring any painful dermatological bedside procedure including: wound debridement, injections and liquid nitrogen application. Patients willing to participate and parents able to consent. Exclusion Criteria: Subjects with a diagnosis of vertigo, inner ear diseases or seizures are excluded due to the uncertainty of performance under VR conditions. Subjects requiring procedures on the head are also excluded to the interference of the VR headset.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Virtual Reality Group<br>This group will receive the virtual reality intervention during out-patient bedside procedures. | Other: Oculus Go Virtual Reality System<br>* The VR system will provide a 3D environment that provides distracting stimulus. Participant will put on the Oculus Go VR system headset 1-2 minutes prior to out-patient bedside procedure up to the completion of procedure which takes typically 3-5 minutes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in average pain as assessed by the visual analog scale (VAS) | VAS has a scoring range from 0 to 10 with 0 being no pain and 10 being the worst possible pain. | Baseline, up to 2 hours | 
| Change in maximum pain level as assessed by VAS | VAS has a scoring range from 0 to 10 with 0 being no pain and 10 being the worst possible pain. | Baseline, up to 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in heart rate | Heart rate will be assessed in beats per minute. | Baseline, up to 2 hours | 
| Change in oxygen saturation | Oxygen saturation will be assessed as a percentage. | Baseline, up to 2 hours | 
| Incidence of intervention related adverse events | Intervention related adverse events will be assessed per treating physician discretion. | Baseline, up to 2 hours |
Lasers in Onychomycosis

Study Overview
=================
Brief Summary
-----------------
Onychomycosis is the most common nail disease, representing more than 50% of all onychopathies. Future studies on the absorption spectra of dermatophyte fungi will be needed to develop lasers that effectively exploit absorption differences in fungi and dermal tissue.

Detailed Description
-----------------
Treatments with antifungals may not be successful due to several factors, including the long time required to apply topical medications, the side effects of systemic drugs, and the application of insufficient medication to the target area. Even with adequate systemic or topical therapy, the persistence of fungal infections is not uncommon. In light of these limitations, laser therapy has been proposed as an alternative option for onychomycosis therapy.

Official Title
-----------------
Comparison Between Different Types of LASER in the Treatment of Onychomycosis, a Randomized Controlled Trial

Conditions
-----------------
Onychomycosis

Intervention / Treatment
-----------------
* Device: Laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with onychomycosis. Exclusion Criteria: Patients with excessive manual work

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: fractional CO2 laser<br>Laser | Device: Laser<br>* Laser<br>|
| Active Comparator: Pulsed dye laser<br>Laser | Device: Laser<br>* Laser<br>|
| Active Comparator: Nd Yag<br>Laser | Device: Laser<br>* Laser<br>|
| Active Comparator: Q switched Nd Yag<br>Laser | Device: Laser<br>* Laser<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Onychomycosis severity index | clinical assessment | change from baseline at 3 months |
Implementing a Healthcare Provider Education Intervention in Rural Communities to Reduce Asthma Morbidity

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to pilot test the implementation of healthcare provider education interventions to improve asthma outcomes in rural youth residing in Bradford County, Florida. The investigators propose to assess the feasibility and acceptability of implementing the Easy Breathing program a rural, medically underserved county and evaluate changes in healthcare provider practices and asthma-related outcomes of rural youth diagnosed with asthma.

Official Title
-----------------
Implementing a Healthcare Provider Education Intervention in Rural Communities to Reduce Asthma Morbidity

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Other: Easy Breathing program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any child between 6 months and 18 years of age at one of the primary care clinics in Braford county. Exclusion Criteria: Unable to meet inclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Easy Breathing<br>Easy Breathing will be implemented in participating clinics. Asthma-related sick visits will be monitored for changes. | Other: Easy Breathing program<br>* Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers will identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in child asthma diagnosis rates | Asthma diagnosis yearly rates (number of children newly diagnosed / number of children seen per year) will be compared before and after implementation of the Easy Breathing program. | Baseline up to Year 1 |
Increased Dietary Protein and Meal Frequency Reduces Total and Abdominal Body Fat During Weight Maintenance and Weight Loss

Study Overview
=================
Brief Summary
-----------------
The purpose of the current study was to examine the impact of macronutrient intake (PRO, 15% vs. 35%) and meal frequency (3 vs. 6 meals/day) on body composition, postprandial thermogenesis and plasma adipokines before and after 28days each of EB (28days) and ED (25%; 28days) in overweight individuals. We hypothesize that HP will elicit more favorable body composition, thermogenic, and cardiometabolic changes than HC intakes and the magnitude of change will be greatest in those consuming HP meals more frequently.

Official Title
-----------------
Increased Protein Intake and Meal Frequency Reduces Abdominal Fat and Increases Postprandial Thermogenesis During Energy Balance and Energy Deficit

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: protein and meal frequency


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30-65 years old, overweight or obese but otherwise in good health Exclusion Criteria: cardiovascular disease, cancer, HTN, type I or II DM, food allergies

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: High protein 3 meals/day<br>35% protein intake eaten as 3 meals per day | Other: protein and meal frequency<br>* comparison of different levels of protein intake and meal frequency on body composition in obese adults<br>|
| Experimental: High carbohydrate consumed 3 meals/day<br>High carbohydrate 3 meals/day | Other: protein and meal frequency<br>* comparison of different levels of protein intake and meal frequency on body composition in obese adults<br>|
| Experimental: High protein consumed 6 meals/day<br>35% protein 6 meals/day | Other: protein and meal frequency<br>* comparison of different levels of protein intake and meal frequency on body composition in obese adults<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| body composition | DXA was used to quantify changes in body composition over the 2 months | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
high protein, high carbohydrate, meal frequency, abdominal body fat, postprandial thermogenesis
Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
The investigators perform a retrospective microarray gene expression profiling study of FFPE from a cohort of DLBCL patients with whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay. The investigators also study the pattern of microRNA from patients with diffuse large B-cell lymphoma. The results of gene expression profiles and microRNA is correlated with clinical outcomes of diffuse large B-cell lymphoma.

Detailed Description
-----------------
Whole genome cDNA mediated Annealing Selection and Ligation (WG-DASL) assay Diffuse large B-cell lymphoma patients Paraffin-embedded tissue End points: Progression-free survival, overall survival Statistics: Leave one-out method Nano string assay for microRNA Diffuse large B-cell lymphoma patients Paraffin-embedded tissue End points: Progression-free survival, overall survival Statistics: Leave one-out method

Official Title
-----------------
Retrospective Analysis of Diffuse Large B-cell Lymphoma: Identification of Factors Associated With Treatment Resistance Via Gene Expression Profile

Conditions
-----------------
Diffuse Large B-cell Lymphoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with diffuse large B-cell lymphoma Patients with tissue blocks available for study Patients with adequate medical records Exclusion Criteria: Patients diagnosed with other subtypes of lymphoma

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diffuse large B-cell lymphoma<br>Patients diagnosed and treated at the Samsung Medical Center | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who relapse or progress after 1st line chemotherapy |  | two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and type of genes and microRNA which are significantly related with relapse or progression (P < 0.05) |  | two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lymphoma, Prognosis, Relapse, Gene, microRNA